EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Suspension-Adapted HEK293FT Cells Enable High-Density Transfection for Efficient Lentiviral Vector Production in CAR-T Therapy

Alexandr Shevtsov iD, Aitolkyn Kydyrbayeva iD, Gaziza Nigmatulla iD, Viktoriya Keyer iD, Tolganay Kulatay, Gulzat Zauatbayeva iD, Bakytkali Ingirbay, Maral Zhumabekova, Dinara Zharlyganova, Alexandr V Shustov iD

Bioengineering · 24.07.2026 · 13 (8) · 856

DOI: 10.3390/bioengineering13080856 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioengineering, online erschienen am 24.07.2026. Verfasst von Alexandr Shevtsov und 9 weiteren Autor:innen. Beteiligte Einrichtung: National Center for Biotechnology, Korgalzhin hwy 13/5, 010000 Astana, Kazakhstan. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Health of the Republic of Kazakhstan, Ministry of Healthcare of the Republic of Kazakhstan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lentiviral vector (LV) production for CAR-T therapy remains challenging due to the limited scalability of adherent HEK293 cell cultures. To address this, we adapted HEK293FT cells directly to serum-free FreeStyle 293 Expression Medium, generating a novel suspension cell line, HEK293FT-DS. We characterized growth kinetics, stability over 35 passages, and transient transfection parameters (PEI:DNA ratio, cell density). The suspension-adapted cells grew with >93% viability and a specific growth rate of 0.54 day−1, and maintained stable viable cell density (1.51 ± 0.03 × 106 cells/mL) over 35 passages. The optimal PEI:DNA ratio was 2.5:1, and increasing the transfection cell density to 16 × 106 cells/mL boosted functional titers to approximately 9 × 106 TU/mL in clarified supernatant. Scaled production (1 L culture supernatant per batch) yielded up to 5 × 109 TU. The resulting vectors efficiently transduced primary human T cells (57% CAR-positive cells) in a CliniMACS Prodigy-based process. The platform based on suspension-adapted HEK293FT-DS cells enables high-density transfection and provides a cost-effective, scalable alternative to commercial LV production systems, particularly suited for academic CAR-T cell manufacturing.

Schlagwörter

Stichwörter der Autor:innen

CAR-T therapyHEK293FT cellsPEI transfectioncell line developmenthigh-density transfectionlentiviral vectorsserum-free mediumsuspension adaptationtransient transfectionviral vector manufacturing

Autor:innen und Institutionen

  • National Center for Biotechnology, Korgalzhin hwy 13/5, 010000 Astana, Kazakhstan.

ORCID-Profile: Alexandr Shevtsov, Aitolkyn Kydyrbayeva, Gaziza Nigmatulla, Viktoriya Keyer, Gulzat Zauatbayeva, Alexandr V Shustov

Förderung

  • Ministry of Health of the Republic of Kazakhstan
  • Ministry of Healthcare of the Republic of Kazakhstan

Zitieren

APA

Shevtsov, A., Kydyrbayeva, A., Nigmatulla, G., Keyer, V., Kulatay, T., Zauatbayeva, G., Ingirbay, B., Zhumabekova, M., Zharlyganova, D., & Shustov, A. V. (2026). Suspension-Adapted HEK293FT Cells Enable High-Density Transfection for Efficient Lentiviral Vector Production in CAR-T Therapy. Bioengineering, 13(8), 856. https://doi.org/10.3390/bioengineering13080856

Vancouver

Shevtsov A, Kydyrbayeva A, Nigmatulla G, Keyer V, Kulatay T, Zauatbayeva G, et al. Suspension-Adapted HEK293FT Cells Enable High-Density Transfection for Efficient Lentiviral Vector Production in CAR-T Therapy. Bioengineering. 2026;13(8):856. doi:10.3390/bioengineering13080856

BibTeX
@article{Shevtsov2026,
  author = {Shevtsov, Alexandr and Kydyrbayeva, Aitolkyn and Nigmatulla, Gaziza and Keyer, Viktoriya and Kulatay, Tolganay and Zauatbayeva, Gulzat and Ingirbay, Bakytkali and Zhumabekova, Maral and Zharlyganova, Dinara and Shustov, Alexandr V},
  title = {Suspension-Adapted HEK293FT Cells Enable High-Density Transfection for Efficient Lentiviral Vector Production in CAR-T Therapy},
  journal = {Bioengineering},
  year = {2026},
  volume = {13},
  number = {8},
  pages = {856},
  doi = {10.3390/bioengineering13080856}
}
Kostenlos starten →